Genentech has received FDA approval for Avastin in combination with intravenous 5-fluorouracil (5-FU)-based chemotherapy for second-line metastatic colorectal cancer. Avastin is also approved as a first-line treatment of metastatic colorectal cancer (CRC) in combination with intravenous 5-FU-based chemotherapy. The approval is based on results of a randomized, controlled, multicenter Phase III trial that showed patients who received Avastin plus the 5-FU-based chemotherapy regimen known as ...